Alpha 2.0
Login Register
» Authors » Scott Reines

Scott Reines

Explore the profile of Scott Reines including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 372
Followers 0
Related Specialties
Psychiatry
Oncology
Neurology
Top 10 Co-Authors
Lucy Lu
Harold Minkowitz
Christopher Lines
Mark Harnett
Michael Ryan
David Leiman
Jarmo Hietala
Richard Hargreaves
Neil Singla
Sant P Chawla
Published In
J Clin Oncol
Int J Neuropsychopharmacol
Pain Ther
Biol Psychiatry
Drugs R D
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy and Safety of Intravenously Administered Tramadol in Patients with Moderate to Severe Pain Following Bunionectomy: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study
Singla N, Pollak R, Gottlieb I, Leiman D, Minkowitz H, Zimmerman J, et al.
Pain Ther . 2020 Jul; 9(2):545-562. PMID: 32683644
Introduction: This study is part of the registrational program for intravenously administered (IV) tramadol in the USA and compared the analgesic benefit and tolerability of two doses of IV tramadol...
2.
IV Tramadol - A New Treatment Option for Management of Post-Operative Pain in the US: An Open-Label, Single-Arm, Safety Trial Including Various Types of Surgery
Minkowitz H, Leiman D, Lu L, Reines S, Ryan M, Harnett M, et al.
J Pain Res . 2020 Jun; 13:1155-1162. PMID: 32547178
Purpose: There is a need to reduce exposure to Schedule II opioids in the United States (US) due to the ongoing opioid epidemic. Schedule II opioids have higher potential for...
3.
Intravenous Tramadol is Effective in the Management of Postoperative Pain Following Abdominoplasty: A Three-Arm Randomized Placebo- and Active-Controlled Trial
Minkowitz H, Salazar H, Leiman D, Solanki D, Lu L, Reines S, et al.
Drugs R D . 2020 May; 20(3):225-236. PMID: 32409981
Background And Objective: Oral tramadol, an atypical opioid approved in the United States (US) since 1995 and a Schedule IV controlled substance, has less abuse liability compared to Schedule II...
4.
Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder
Michelson D, Hargreaves R, Alexander R, Ceesay P, Hietala J, Lines C, et al.
Int J Neuropsychopharmacol . 2012 Mar; 16(1):1-11. PMID: 22433185
Preclinical studies suggest that substance P acting at neurokinin 1 (NK1) receptors may be involved in stress responses and NK1 receptor antagonists show activity in tests of anxiety. These data...
5.
Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial
Saper J, Dahlof C, So Y, Tfelt-Hansen P, Malbecq W, Loeys T, et al.
Headache . 2006 Feb; 46(2):264-75. PMID: 16492236
Objective: To investigate the efficacy, tolerability, and safety of rofecoxib and ibuprofen for acute migraine treatment. Background: Rofecoxib was effective and well tolerated in a previous study of treatment of...
6.
Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder
Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, et al.
Biol Psychiatry . 2005 Oct; 59(3):216-23. PMID: 16248986
Background: An early clinical trial suggested that the substance P (neurokinin(1) receptor) antagonist, aprepitant, might provide a unique mechanism of antidepressant activity. Phase III trials were conducted to confirm these...
7.
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052...
Hesketh P, Grunberg S, Gralla R, Warr D, Roila F, de Wit R, et al.
J Clin Oncol . 2003 Oct; 21(22):4112-9. PMID: 14559886
Purpose: In early clinical trials with patients receiving highly emetogenic chemotherapy, the neurokinin antagonist aprepitant significantly enhanced the efficacy of a standard antiemetic regimen consisting of a type-three 5-hydroxytryptamine antagonist...